NAD-boosting treatment shows no Parkinson's benefit in yearlong trial
A yearlong clinical trial of 410 patients found that nicotinamide riboside (NR) provided no clinical benefit for early-stage Parkinson's disease. The study showed that patients taking the supplement performed slightly worse than those on a placebo.
Why it matters
This finding helps clarify the efficacy of NAD-boosting supplements, preventing patients from relying on ineffective treatments for neurodegenerative conditions.
edited by Gaby Clark , reviewed by Robert Egan
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add to Preferred Sources Credit: Image generated by the editorial team using AI for illustrative purposes. A major clinical trial involving 410 people with early Parkinson's disease has found no clinical benefit from nicotinamide riboside (NR), a compound that increases cellular levels of nicotinamide adenine dinucleotide (NAD). The findings are published in JAMA .
The NOPARK trial was led by professor Charalampos Tzoulis at Haukeland University Hospital and the University of Bergen. Participants at 11 Norwegian centers were randomly assigned to receive either NR or placebo for one year. Neither the participants nor the study teams knew who received which treatment.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in